Suppr超能文献

美国消费者对不同版本药品安全信息的理解、偏好及反应:一项随机对照试验

Consumer Understanding, Preferences, and Responses to Different Versions of Drug Safety Messages in the United States: A Randomized Controlled Trial.

作者信息

McCormack Lauren, Craig Lefebvre R, Bann Carla, Taylor Olivia, Rausch Paula

机构信息

Center for Communication Science, RTI International, 3040 East Cornwallis Road, Research Triangle Park, NC, 27709-2194, USA.

Division for Statistics and Data Sciences, RTI International, Research Triangle Park, NC, USA.

出版信息

Drug Saf. 2016 Feb;39(2):171-84. doi: 10.1007/s40264-015-0358-9.

Abstract

INTRODUCTION

As part of its mission, the US Food and Drug Administration (FDA) communicates with the public regularly about the benefits and risks of prescription and over-the-counter (OTC) drugs. Effectively communicating risk, however, is a significant public health challenge.

OBJECTIVE

To better understand how different populations understand information communicated by the FDA about drug safety, we conducted a randomized experiment to examine comprehension and other measures of effectiveness of drug safety messages that occurred in a post-market surveillance phase.

METHODS

We used an Internet panel survey of 1244 consumers, of whom 58% used prescription drugs in the past year. Half of the sample panel was randomized to read a previous FDA Drug Safety Communication (DSC) with the drug name changed, and the other half was randomized to read a revised version of the same DSC. We examined how making certain modifications to the way drug risk information is communicated has an impact on comprehension and behavioral intentions, including the user's likelihood of discontinuing the drug. We also studied how comprehension varied by respondent characteristics, health literacy skills, risk perceptions, and trust in the message.

RESULTS

Based on a five-item comprehension index, the revised version of the message was associated with significantly greater comprehension of the information relative to the standard version (63 vs 52% correct, p < 0.001). Significantly more respondents found the revised version to be clear (82 vs 73%, p < 0.000), while fewer in that group reported learning something new (78% vs 84%, p = 0.015). No significant differences emerged between the two groups in terms of the message being informative, convincing, or helpful. We found no significant differences between the two groups in terms of behavioral intentions, risk perception, and trust.

CONCLUSIONS

We found that making plain language changes to the DSC significantly increased consumers' level of comprehension of its content, providing support for ongoing use and further exploration of these strategies in pharmacovigilance communication research. The study findings have important implications for future drug safety and other communication messages related to prescription drugs.

摘要

引言

作为其使命的一部分,美国食品药品监督管理局(FDA)定期与公众就处方药和非处方药(OTC)的益处和风险进行沟通。然而,有效地传达风险是一项重大的公共卫生挑战。

目的

为了更好地了解不同人群如何理解FDA传达的关于药物安全的信息,我们进行了一项随机实验,以检验在上市后监测阶段发布的药物安全信息的理解程度及其他有效性指标。

方法

我们对1244名消费者进行了一项互联网小组调查,其中58%的人在过去一年中使用过处方药。样本小组的一半被随机分配阅读一份药物名称已更改的FDA先前药物安全通讯(DSC),另一半被随机分配阅读同一DSC的修订版。我们研究了对药物风险信息传达方式进行某些修改如何影响理解程度和行为意图,包括用户停药的可能性。我们还研究了理解程度如何因受访者特征、健康素养技能、风险认知以及对信息的信任度而有所不同。

结果

基于一个包含五个项目的理解指数,与标准版本相比,信息的修订版与对信息的显著更高理解程度相关(正确理解率分别为63%和52%,p < 0.001)。显著更多的受访者认为修订版清晰明了(82%对73%,p < 0.000),而该组中报告学到新东西的受访者较少(78%对84%,p = 0.015)。在信息的信息量、说服力或帮助性方面,两组之间没有显著差异。在行为意图、风险认知和信任方面,两组之间也没有显著差异。

结论

我们发现,对DSC进行通俗易懂的语言修改显著提高了消费者对其内容的理解程度,为在药物警戒沟通研究中持续使用和进一步探索这些策略提供了支持。研究结果对未来的药物安全及其他与处方药相关的沟通信息具有重要意义。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4273/4735220/c70b542a2467/40264_2015_358_Fig1_HTML.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验